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Abstract 
Myocilin glaucoma is an autosomal dominant disorder leading to irreversible blindness, but 
early intervention can minimize vision loss and delay disease progression. The purpose of 
this study was to discuss the benefits of predictive genetic testing in minors for Myocilin 
mutations associated with childhood onset glaucoma. Three families with Myocilin mutations 
associated with an age of onset before 18 years and six unaffected at-risk children were 
identified. Predictive genetic testing was discussed with the parents and offered for at risk 
minors. Parents opted for genetic testing in half of the cases. None carried the familial 
mutation. The age of disease onset in the family, the severity of the condition, and the age of 
the child are all factors that appear to influence the decision of the parent to test their 
children. Predictive genetic testing for early onset Myocilin glaucoma can facilitate early 
detection of disease or discharge from routine ophthalmic examinations. 
  
INTRODUCTION 
Glaucoma is a leading cause of irreversible blindness worldwide, affecting 3% of the 
population over the age of 50 (1). The most common type is Primary Open Angle Glaucoma 
(POAG, MIM 137760) characterized by optic nerve damage with open drainage angles (2). 
Juvenile Open Angle Glaucoma (JOAG) is defined arbitrarily as diagnosis prior to age forty 
and is usually associated with a more severe phenotype (3). The early stages are 
asymptomatic and irreversible blindness may occur if left untreated. Therapeutic and/or 
surgical interventions aim at controlling intraocular pressure (IOP), and are usually effective 
in minimizing loss of visual function and delaying progression of the disease (4, 5). 
Pathogenic variants in the Myocilin gene (MIM 601652) are the commonest cause of 
inherited POAG. We have previously reported a prevalence of 4% in POAG and 17% in 
JOAG in the Australian population (6). Myocilin glaucoma is inherited in an autosomal 
dominant manner and is usually associated with high IOP and earlier age of onset than other 
unselected glaucoma cases (6). Genotype-phenotype correlations exist with some mutations 
associated with a very young age of onset, as early as the teens or childhood (6-8). 
Considering that effective treatments which minimize vision loss are available, it becomes 
important to identify at-risk individuals before any irreversible damage occurs. Adequate 
identification of families with onset of glaucoma in childhood is essential as children can 
benefit from early genetic testing. In this study, we report on 3 families with known 
pathogenic Myocilin variants associated with very early age of onset for which predictive 
genetic testing for unaffected minors was discussed. 
 
 
 
 
MATERIALS AND METHODS 
This study was approved by the Southern Adelaide Clinical Human Research Ethics 
Committee and was conducted in accordance with the National Health and Medical Research 
Council statement of ethical conduct in research involving humans. 
Patients were recruited through the Australian and New Zealand Registry of Advanced 
Glaucoma (ANZRAG) via referral from their treating specialist as previously reported (9). 
Myocilin sequencing was performed through an accredited laboratory as described previously 
(6). When a pathogenic variant was identified, genetic counselling was offered and Myocilin 
genetic testing was made available to family members. Contact was made only through the 
proband referring relatives to the ANZRAG in order to promote a voluntary decision. In 
cases with an age at diagnosis of less than 18 years reported in the family or in the literature 
for the sequence variant in question, predictive genetic testing of unaffected minors was 
discussed with the children’s parents and their treating specialist. Genetic counselling was 
provided, written informed consent was obtained from the parents and where possible 
children gave assent, and a blood sample was provided for the purpose of predictive genetic 
testing. 
 
RESULTS 
In the ANZRAG, Myocilin mutations are present in 4% of our POAG cases (50/1248).  
Among these, three families with Myocilin mutations associated with an age of onset before 
18 years and six first-degree at-risk minors were identified (Figure 1). Predictive genetic 
testing was discussed with the parents, and three children from two families were tested. The 
clinical details of the three families are presented in Table 1. 
The proband from Family A (III-1) was diagnosed at 11 years old. At the age of 17, she 
required trabeculectomy to control her glaucoma. She had a very strong family history of 
severe JOAG with her daughter, father, sister, as well as a grandmother, aunt and cousin on 
the paternal side affected. All affected relatives were diagnosed in their childhood or teens, 
and all required glaucoma surgery. 
Myocilin sequencing in the proband identified the previously reported mutation p.T438I 
(c.1313C>T). The mutation segregated with the condition in four affected family members. 
The proband’s son (IV-1), aged 17 had normal IOP. Her nephew (IV-3), aged 3 is reported to 
be unaffected but has not been clinically examined. Myocilin predictive genetic testing of 
both children was requested by their respective parents. Neither child carried the familial 
mutation. 
In Family B, the proband (III-2) was noted to have increased IOP and optic nerve changes 
consistent with JOAG at age 13. He presented at age 17 with a left ischemic central retinal 
vein occlusion which left the eye blind from retinal ischemia and uncontrolled glaucoma. 
Despite regular ophthalmic follow-up and topical therapy, there were periods of non-
compliance, and at age 34 with uncontrolled IOP and worsening visual fields, he underwent a 
right trabeculectomy. His most recent visual field test is displayed in Figure 2. The patient 
had a significant family history of glaucoma with his father and paternal grandfather 
diagnosed with glaucoma in their teens. 
Myocilin sequencing identified the previously reported mutation p.G367R (c.1099G>A) in 
the proband and his father (II-3). The proband’s 10 year old son (IV-3) had normal IOP and 
optic nerves. Testing was requested by his father and results were negative for the familial 
mutation. 
The proband from Family C (III-1) was diagnosed at 20 years old with significantly elevated 
IOP. She had laser trabeculoplasty and was on maximal medical therapy to control her IOP. 
Visual fields were largely intact but there was possibly an early defect on the right side 
(Figure 2). There is a positive family history with a sister, father and paternal grandfather 
diagnosed with JOAG and requiring glaucoma filtration surgery to control their IOP. 
The p.G367R (c.1099G>A) Myocilin mutation was identified in the proband and her sister. 
The proband’s daughter (IV-1) aged 3, and her sister’s sons (IV-3, IV-4), aged 1 and 3 have 
not been examined but were said to be unaffected. Predictive genetic testing of the three 
children was discussed with the parents but they decided to defer testing until the children 
were older. 
 
DISCUSSION 
While predictive genetic testing for adult or late onset conditions is accepted in adults, the 
international consensus is that such testing in minors should be deferred until they are old 
enough to make an informed decision (10). However, genetic testing for diseases that have 
childhood onset, where established early surveillance or treatment may alter the course of the 
disease, is generally supported (10, 11). This approach is mainly endorsed by the immediate 
and direct medical benefits for the child. Myocilin POAG is typically an adult-onset 
condition, however some mutations are known to be associated with a juvenile-onset (6-8). In 
these situations, predictive genetic testing of minors should be considered, particularly as 
POAG is difficult to clinically diagnose in its early stages, and earlier detection and 
intervention lead to better visual outcomes. 
Based on these considerations, through the ANZRAG we identified three families with 
Myocilin mutations associated with very early age of onset POAG that could benefit from 
predictive genetic testing of at-risk minors. These families displayed two previously reported 
Myocilin mutations: p.T438I and p.G367R. Both variants have previously been reported in 
individuals displaying an age at diagnosis in childhood or early adulthood, significantly 
elevated IOP, and glaucoma surgery required for most individuals (7, 8, 12-15). Family A 
carrying p.T438I, exhibited a similar phenotype. In Family B, the two affected individuals 
carrying p.G367R were diagnosed in their mid-teen years, and progressed to severe visual 
impairment by their mid-20s. In contrast, the two affected individuals from Family C 
carrying the same mutation presented in their early twenties and their glaucoma was not as 
advanced. 
Among all three families, six unaffected children were identified as being at risk of carrying 
the familial Myocilin mutation. The parents of three of the children from two families (A & 
B) decided to opt for genetic testing and these three children did not carry the familial 
mutations. The third family (C) decided to defer testing. We previously showed that 
individuals who have a higher perceived severity of glaucoma and/or a higher perceived risk 
of developing glaucoma are more likely to act upon it (16). The two families who decided on 
testing their children had strong family histories of glaucoma developing during childhood or 
early teens, with some individuals having severe glaucoma and two of the children tested 
were getting near the age of onset of the familial mutations. Family C had so far experienced 
less severe glaucoma and vision loss than the affected members of Family B carrying the 
same mutation (Figure 2), had a later onset and the at-risk children were of younger age, 
which could account for their decision of deferring testing. 
When counselling parents on deciding whether to test or not, the benefits and potential harms 
need to be reviewed and the best interests of the child should always be central to any 
decision. Medical benefits include close monitoring and surveillance to detect glaucoma signs 
at the earliest possible time point, and early intervention and/or treatment to prevent or 
minimize damage to the optic nerve and associated vision loss in the case of a positive 
genetic result. If results are negative, the advantages are reduced number of visits and eye 
exams required, including potential examination under anesthesia in the cases of very young 
children. Psychosocial benefits include the removal of uncertainty and the opportunity for 
adjusting life plans. Potential harms for the child are mainly psychosocial in nature, including 
the alteration of self-image and self-esteem, increased anxiety, negatively altered life choices 
and potential for discrimination and stigmatization (10, 17). Distortion of parental perception 
and education of the child, parental anxiety and a potentially negative impact on the extended 
family dynamics are other potential harms to be considered. 
The timing of testing for childhood onset conditions that have therapeutic options is an 
important question (11). A reasonable approach for Myocilin JOAG would be to offer testing 
near the age considered adequate for starting medical surveillance and/or interventions. This 
age could vary depending on the familial variant but should be based on the age at diagnosis 
within the family, and the reported age of onset for that variant in the literature.  
The acceptability and the psychosocial experience of adults undergoing predictive genetic 
testing for glaucoma have been previously documented (16, 18). However, there are few 
studies on the psychosocial impact of genetic testing on children in general. A recent review 
of the literature did not suggest that a child’s emotional state, self-perception or social 
wellbeing were significantly affected by predictive genetic testing (17). Future research will 
be needed to understand the potential impacts of predictive genetic testing for glaucoma in 
minors to better counsel the families. 
In conclusion, we identified three families with Myocilin JOAG who could benefit from 
predictive genetic testing of at-risk minors in view of the potential immediate medical 
benefits for the children. Three children were found not to carry the familial mutation, 
removing the need for unnecessary regular ophthalmic examinations. The decision for testing 
seemed to be influenced by the personal experience of the family in question with glaucoma. 
Knowing how to better counsel parents during the decision making process, the best age to 
undergo testing, and the potential impact of the testing are key areas of future focus which 
will lead to better outcomes in families affected with early age of onset Myocilin glaucoma.  
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Figure 1 
Pedigree of the families 
     
Round symbols indicate females; square symbols, males; fully filled symbols, primary open-angle glaucoma; unfilled symbols, unaffected; 
diagonal line, deceased; arrow, proband; P, pregnancy; wt: wild-type allele. The age of the at-risk children is displayed at the bottom. 
  
Figure 2 
Visual Fields of the proband from Family B (III-2) and Family C (III-1) with the p.G367R Myocilin mutation. Note: As Individual III-2 from 
Family B is blind in his left eye, visual fields of both individuals are only displayed for the right eye.  
 
RE: Right eye 
Table 1 
Clinical details and genetic results of the recruited individuals 
Patient Age at 
examination 
(years) 
Phenotype Myocilin 
mutation 
Age at 
diagnosis 
(years) 
Maximum IOP           
(mmHg, RE/LE) 
BCVA 
(RE:LE) 
CDR 
(RE/LE) 
Glaucoma 
surgery 
Family A         
II-3 70 JOAG T438I 14 na 20/40:20/30 na Yes 
II-4 75 JOAG T438I 11 25/20 20/20:20/20 0.8/0.6 Yes 
  III-1* 43 JOAG T438I 11 16/31 20/25:20/25 0.4/1.0 Yes 
III-2 42 JOAG T438I 7 na na na Yes 
IV-1 18 JOAG T438I 17 44/46 na 0.7/0.7 No 
IV-2 17 Unaffected wt  16/17 na na No 
IV-3 3 Unaffected wt  na na na No 
Family B         
II-3 62 JOAG G367R 14 na 20/16:20/30 0.6/0.99 Yes 
  III-2* 34 JOAG G367R 13 40/40 20/40:NLP 0.9/1.0 Yes 
IV-3 10 Unaffected wt  13/13 20/25:20/25 0.3/0.3 No 
Family C         
  III-1* 31 JOAG G367R 20 35/35 20/16:20/16 0.3/0.4 No 
III-2 33 JOAG G367R 23 32/33 20/20:20/20 0.7/0.6 Yes 
IOP: Intraocular pressure, BCVA: Best corrected visual acuity, CDR: Cup to disc ratio, RE: right eye, LE: left eye, na: not available, JOAG: 
Juvenile Open-Angle Glaucoma, *: proband, wt: wild-type allele 
